Estudio piloto, randomizado, controlado con placebo | 07 MAR 21

Eficacia de Nitazoxanida en la reducción de la carga viral en pacientes con COVID-19

El efecto antiviral observado in vitro, parecería verificarse en pacientes con infección por COVID-19 leve a moderada
Autor/a: Marcelo Silva, Andrés Espejo, María L Pereyra, Martín Lynch, Marcos Thompson, Hernán Taconelli, Patricia Bare, Matias J Pereson, Marcelo Garbini, Pablo Crucci, Diego Enriquez 
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas
  1. Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med. 2021;181(2):195–202. doi:10.1001/jamainternmed.2020.6319.
  2. Ashiru O, Howe JD, Butters TD. Nitazoxanide, an antiviral thiazolide, depletes ATP- sensitive intracelular Ca (2+) stores. Virology. 2014;462-463:135‐148. doi:10.1016/j.virol. 2014.05.015
  3. Balderas-Acata J, Bueno E, Pérez-Becerril F, et al. (2011). Bioavailability of Two Oral-Suspension Formulations of a Single Dose of Nitazoxanide 500 mg: An Open-Label, Randomized-Sequence, Two-Period Crossover, Comparison in Healthy Fasted Mexican Adult Volunteers. Journal of Bioequivalence & Bioavailability. 03. 10.4172/jbb.1000056.
  4. Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the
  5. treatment of COVID-19: final report. N Engl J Med 2020;383:1813-26. DOI: 10.1056/NEJMoa2007764. Published online October 8 and updated on October 9, 2020, at NEJM.org, 2020.
  6. Cascella, M., Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Oct4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearlsPublishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
  7. Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol.Jan 2010;84(3):1289–1301. doi:10.1128/JVI.01281-0915.
  8. Chen P, Nirula A, Heller b. et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 2021;384:229-37. DOI: 10.1056/NEJMoa2029849.
  9. ClinicalTrails.gov.https://clinicaltrials.gov/ct2/results?cond=COVID&term=Nitazoxanide&cntry=&state=&city=&dist=.
  10. De Chang D, Mo G, Yuan X, et al. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. Am J Respir Crit CareMed. 2020;201(9):1150‐1152. doi:10.1164/rccm.202003-0524LE.
  11. Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo controlled, phase 2b/3trial. Lancet Infect Dis. 2014;14(7):609–618. doi:10.1016/S1473-3099(14)70717-0.
  12. Hong S, Kim HJ, Song CS et al Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mic
 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024